Orchid Pharma (LUX:ORCHP) Long-Term Debt: $35.31 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LUX:ORCHP Orchid Pharma Ltd LUX:ORCHP
59 GF Score
Price $5.45
GF Value $4.49
! 10 Warning Signs
View Full Analysis

What is Orchid Pharma Long-Term Debt?

Orchid Pharma LUX:ORCHP 59 Long-Term Debt is $35.31 Mil as of Mar. 2026. GuruFocus rates LUX:ORCHP with a GF Score™ of 59/100 and a GF Value™ of $4.49. The stock has 10 warning signs investors should review.

Orchid Pharma's Long-Term Debt for the quarter that ended in Mar. 2026 was $35.31 Mil.

Orchid Pharma's quarterly Long-Term Debt declined from Sep. 2025 ($26.50 Mil) to Dec. 2025 ($0.00 Mil) but then increased from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($35.31 Mil).

Orchid Pharma's annual Long-Term Debt increased from Mar. 2024 ($14.51 Mil) to Mar. 2025 ($15.21 Mil) and increased from Mar. 2025 ($15.21 Mil) to Mar. 2026 ($35.31 Mil).

Orchid Pharma  (LUX:ORCHP) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Orchid Pharma Long-Term Debt Related Terms

Orchid Pharma Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Orchid Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orchid Pharma Long-Term Debt Chart

Orchid Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.32 18.09 14.51 15.21 35.31

Orchid Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.21 0.00 26.50 0.00 35.31
LUX:ORCHP
59GF Score
Orchid Pharma Ltd LUX:ORCHP
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $35.31 Mil mean?
Orchid Pharma (LUX:ORCHP) has a Long-Term Debt of $35.31 Mil as of Mar. 2026.
Is Orchid Pharma's Long-Term Debt too high?
Orchid Pharma's current Long-Term Debt is $35.31 Mil. Overall, Orchid Pharma has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's Long-Term Debt compare to ZTS and UTHR?
Orchid Pharma's Long-Term Debt of $35.31 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Orchid Pharma's current Long-Term Debt is $35.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (LUX:ORCHP) has a current Long-Term Debt of $35.31 Mil. The stock's GF Value™ is $4.49, compared to a current price of $5.45 — trading 21.4% above its estimated fair value. The current Long-Term Debt is $35.31 Mil. Orchid Pharma's overall GF Score™ is 59/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Orchid Pharma (LUX:ORCHP), the current Long-Term Debt is $35.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orchid Pharma (LUX:ORCHP) Overvalued in 2026?

Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued. The current stock price of $5.45 is trading 21.4% above its estimated GF Value™ of $4.49.

Key valuation signals for LUX:ORCHP:

  • Long-Term Debt: $35.31 Mil
  • GF Value™: $4.49 vs. price of $5.45 (21.4% above fair value)
  • GF Score™: 59/100 with 10 warning signs

No single metric tells the full story. See the LUX:ORCHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orchid Pharma Business Description

Address Sector 74A, 15th Floor, Tower-1, DLF Corporate Greens, Narsinghpur, Gurugram, HR, IND, 122004
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
59GF Score

Get the complete analysis for LUX:ORCHP

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.45
Price
$4.49
GF Value